Clinical Development

Brought to you by:

relay

Biotech

Immunovant posts phase 3 autoimmune win but won't seek approval

Having made a next-gen asset its lead prospect last year, the biotech isn’t currently planning to file for batoclimab approval in myasthenia gravis.

Nick Paul Taylor Mar 19, 2025 9:15am

positive negative up down good bad mixed

Incyte posts phase 3 skin condition wins but details disappoint

Mar 17, 2025 8:12am

An arrow incrementally going up stairs before pointing straight up Blue background

AstraZeneca's $800M rare disease bet hits primary phase 3 goal

Mar 17, 2025 7:25am

whale jumping out of water

Orca prepares to make market plunge after phase 3 win

Mar 17, 2025 7:00am

HIV AIDS PREP

GSK posts data on HIV assets vying for roles in 6-month combo

Mar 12, 2025 11:25am

Kidneys brightly lit

Arrowhead shares ‘select’ data for RNAi asset in kidney trial

Mar 10, 2025 11:55am